Search results for "Dermatologic agents"

showing 10 items of 25 documents

Keratoacanthoma Centrifugum Marginatum (KCM) after photodynamic therapy with good response to oral retinoids and topical 5‐fluorouracil

2019

Keratoacanthoma centrifugum marginatum (KCM) is a rare variant of keratoacanthoma (KA), characterized by progressive peripheral growth, and usually devoid of deep invasion. Different systemic (oral retinoids) or topical treatments have been reported, but there is not a well-defined therapeutic protocol. We report the case of a KCM developing after photodynamic therapy (PDT) on the right leg of a 64-year-old woman. It was treated successfully with oral acitretin combined with topical 5-Fluorouracil + salicylic acid for 5 months. This is the first case of KCM developing after PDT and successfully treated with oral retinoid combined with topical treatment.

Keratoacanthomamedicine.medical_specialtymedicine.medical_treatmentAdministration OralTopical treatmentPhotodynamic therapyDermatologyAdministration CutaneousAcitretinRetinoids030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineHumansbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseDermatologyAcitretinKeratoacanthomaTreatment OutcomePhotochemotherapyFluorouracil030220 oncology & carcinogenesisFemaleDermatologic AgentsFluorouracilbusinessOral retinoidmedicine.drugDermatologic Therapy
researchProduct

Diagnosis and therapy of cutaneous and mucocutaneous Leishmaniasis in Germany

2011

The incidence of cutaneous and mucocutaneous Leishmaniasis (CL/MCL) is increasing globally, also in Germany, although the cases are imported and still low in number. The current evidence for the different therapies has many limitations due to lack of sufficient studies on the different Leishmania species with differing virulence. So far there is no international gold standard for the optimal management. The aim of the German joint working group on Leishmaniasis, formed by the societies of Tropical Medicine (DTG), Chemotherapy (PEG) and Dermatology (DDG), was to establish a guideline for the diagnosis and treatment of CL and MCL in Germany, based on evidence (Medline search yielded 400 artic…

Leishmaniasis Mucocutaneousmedicine.medical_specialtymedicine.medical_treatmentParomomycinCryotherapyDermatologyPharmacotherapyCutaneous leishmaniasisPregnancyGermanyparasitic diseasesmedicineHumansMiltefosineAntiparasitic Agentsbusiness.industryLeishmaniasismedicine.diseaseDermatologyLymphangitisPregnancy Complications ParasiticFemaleDermatologic AgentsbusinessFluconazolemedicine.drugJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Emerging drugs for the treatment of vitiligo.

2020

Introduction: Vitiligo is a relatively common autoimmune depigmenting disorder of the skin. There has been a great advance in understanding the pathological basis, which has led to the development and utilization of various new molecules in treating vitiligo. This review aims at a comprehensively describing the treatments available and the emerging treatment aspects and the scope for future developments.Areas covered: This study comprehensively summarizes the current concepts in the pathogenesis of vitiligo with special focus on the cytokine and signaling pathways, which are the targets for newer drugs. JAK kinase signaling pathways and the cytokines involved are the focus of vitiligo treat…

MAP Kinase Signaling SystemAdministration TopicalVitiligoAdministration OralVitiligoBiologicsBioinformatics030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineClinical Trials Phase II as TopicLocalized vitiligoMedicineHumansJanus Kinase InhibitorsPharmacology (medical)skin and connective tissue diseasesRandomized Controlled Trials as TopicPharmacologytreatmentintegumentary systembusiness.industrymedicine.diseaseCombined Modality TherapyJAK inhibitorchemistryClinical Trials Phase III as Topic030220 oncology & carcinogenesisCytokinesAfamelanotideDermatologic AgentsbusinessJanus kinaseBiologics; JAK inhibitor; treatment; vitiligoExpert opinion on emerging drugs
researchProduct

Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study

2019

Abstract Background Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. Aims to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. Methods This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. Results Seventy patients (64 Crohn’s disease…

MaleCrohn’s diseaseSettore MED/16 - REUMATOLOGIAPsoriaticCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Hepatology; GastroenterologyInflammatory bowel disease0302 clinical medicineClinical endpointCrohn's disease Psoriasis Psoriatic arthritis Ulcerative colitis UstekinumabCrohn's diseaseSettore MED/12 - GastroenterologiaGastroenterologyMiddle AgedUlcerative colitisCrohn's diseaseTreatment OutcomeItaly030220 oncology & carcinogenesisPsoriatic arthritis030211 gastroenterology & hepatologyFemaleUstekinumabmedicine.drugAdultmedicine.medical_specialty03 medical and health sciencesPsoriatic arthritisCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Adult; Aged; Arthritis Psoriatic; Dermatologic Agents; Female; Humans; Inflammatory Bowel Diseases; Italy; Logistic Models; Male; Middle Aged; Psoriasis; Retrospective Studies; Treatment Outcome; Ustekinumab; Young AdultYoung AdultInternal medicinePsoriasisUstekinumabmedicineHumansPsoriasisAgedRetrospective StudiesHepatologybusiness.industryArthritisArthritis Psoriaticmedicine.diseaseInflammatory Bowel Diseasesdigestive system diseasesCrohn’s disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; UstekinumabLogistic ModelsUlcerative colitisConcomitantDermatologic Agentsbusiness
researchProduct

Low dose of isotretinoin: A comprehensive review

2020

Isotretinoin is a first-generation retinoid initially approved for the treatment of severe cases of acne vulgaris (nodulocystic acne). Because of its broad anti-inflammatory and immunomodulatory properties, it has been used beyond its initial approval in a myriad of other indications. Adverse effects of isotretinoin vary from xerosis to teratogenicity. Herein, we reviewed the literature, through date-unlimited PubMed search, from inception till December 2019, using the following search terms: "low-dose isotretinoin" and "dermatology," "isotretinoin and safety," "isotretinoin, off-label uses," "isotretinoin and male fertility," "isotretinoin, iPLEDGE system," aiming to deliver a therapeutic …

Malemedicine.medical_specialtyNodulocystic acneDermatologyRetinoids030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineAcne VulgarismedicineHumansIsotretinoinskin and connective tissue diseasesAdverse effectIsotretinoinAcnebusiness.industryLow doseGeneral Medicinemedicine.diseaseDermatologyClinical PracticeSafety profileSearch terms030220 oncology & carcinogenesisDermatologic Agentsbusinessmedicine.drugDermatologic Therapy
researchProduct

Exogenous ochronosis and striae atrophicae following the use of bleaching creams.

2005

Exogenous ochronosis is a paradoxical hyper-pigmentation of the skin caused by the long-term use of hydroquinone-containing bleaching creams. Ochronosis is an uncommon condition characterized by yellow-brown pigmented deposits in the dermis. We report two cases of exogenous ochronosis in two female patients of the sub-Saharan African population. The lesions were characterized by an asymptomatic hyper-pigmentation of the face with gradually progressive blue-black macular patches, and in case no. 2, in addition to dyschromic lesions, striae atrophicae were present. This phenomenon is the outcome of the use of skin care products containing high concentrations of hydroquinone- and glucocorticoi…

Pathologymedicine.medical_specialtyDermatology.DermisHyperpigmentationFemale patientmedicineHumansGlucocorticoidsPigmentation disorderStriae atrophicaeSkinSkin careOchronosisExogenous ochronosisbusiness.industryMiddle Agedmedicine.diseaseHydroquinonesmedicine.anatomical_structureAfrican populationFemalesense organsDermatologic AgentsAtrophybusinessOchronosisInternational journal of dermatology
researchProduct

A gas chromatography-mass spectrometric method to determine skin-whitening agents in cosmetic products.

2010

An analytical method is proposed here to determine three allowed (kojic acid, azelaic acid and arbutin) and two forbidden (resorcinol and hydroquinone) skin-whitening agents in cosmetics. The method is based on gas chromatography coupled with mass spectrometric detection, which allows the two prohibited target compounds to be identified unequivocally by means of their mass spectra acquired in full-scan mode at the retention time of these compounds. Owing to their low volatility, target analytes are derivatized using N,O-bis-(trimethylsilyl)trifluoroacetamide (BSTFA) (containing 1% trimethylchlorosylane) prior to injection into the chromatographic system. The accuracy and precision of the pr…

Trimethylsilyl CompoundsAzelaic acidChromatographyTime FactorsPigmentationmedia_common.quotation_subjectArbutinTemperatureResorcinolCosmeticsResorcinolsBSTFAMass spectrometryCosmeticsGas Chromatography-Mass SpectrometryAnalytical Chemistrychemistry.chemical_compoundchemistrymedicineGas chromatographyDermatologic AgentsGas chromatography–mass spectrometrymedia_commonmedicine.drugSkinTalanta
researchProduct

Current management of atopic dermatitis and interruption of the atopic march.

2003

Treatment of atopic dermatitis requires a comprehensive approach that includes evaluation of potential triggers and education of the patient and family regarding proper avoidance measures. Hydration of the skin and maintenance of an intact skin barrier remain integral to proper management. Although topical corticosteroids have been a mainstay of anti-inflammatory therapy, the newer topical calcineurin inhibitors offer advantages for treatment of this chronic, relapsing disease. Studies aimed at defining optimal combination therapy and early intervention might change the treatment paradigm for atopic dermatitis.

medicine.medical_specialtyAllergyImmunologyCalcineurin InhibitorsAnti-Inflammatory AgentsDiseaseEczema Area and Severity IndexDermatitis AtopicAtopyPrevalenceImmunology and AllergyMedicineHumansSCORADAsthmamedicine.diagnostic_testbusiness.industryCalcineurinDisease ManagementAtopic dermatitismedicine.diseaseSkin CareDermatologyAsthmabody regionsCalcineurinDisease ProgressionDermatologic AgentsbusinessThe Journal of allergy and clinical immunology
researchProduct

Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum

2019

Introduction: Pyoderma gangrenosum (PG) is a noninfectious, reactive inflammatory neutrophilic dermatosis that is commonly associated with autoimmune and neoplastic disorders. There are emerging diagnostic tools and treatment options for PG.Area covered: The diagnosis of PG should be seriously considered when managing ulcers to avoid unnecessary medical and surgical complications with prompt and suitable treatment. There are no standardized treatment guidelines for PG, and current therapy largely depends on the severity and progression of the disease. Systemic corticosteroids, immunosuppressant therapy, and biologic agents remain mainstay therapies. In this article, we present a literature …

medicine.medical_specialtyDiseaseDiagnostic toolsSeverity of Illness Index030226 pharmacology & pharmacySystemic therapyBiological Factors03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesmedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsIntensive care medicineClinical treatmentbusiness.industryGeneral MedicineGold standard (test)medicine.diseasePyoderma GangrenosumBiologic AgentsNeutrophilic dermatosis030220 oncology & carcinogenesisDisease ProgressionDermatologic AgentsbusinessImmunosuppressive AgentsPyoderma gangrenosumExpert Review of Clinical Pharmacology
researchProduct

Compounded preparations in dermatology – analysis of prescribing habits in everyday clinical practice in Germany

2020

Background Compounded preparations (CPs) are an indispensable addition to approved, commercially available drugs (CADs), especially for topical therapy. In Germany, about eight million CPs are prescribed within the statutory health insurance system each year, 50 % thereof by dermatologists. Methods We analyzed prescribing habits based on a questionnaire sent out to 186 office-based dermatologists and 1,491 pharmacies in the federal states of Rhineland-Palatinate and Saarland. The goal was to improve patient care by collecting and categorizing data in terms of prescription practice and associated challenges in interdisciplinary cooperation. Results Overall, 351 pharmacists (23.5 %) and 53 de…

medicine.medical_specialtyDrug CompoundingMEDLINEContext (language use)PharmacyDermatologyPharmacistsSkin Diseases030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineContinuing medical educationGermanySurveys and QuestionnairesHumansMedicinePractice Patterns Physicians'Medical prescriptionPharmaciesbusiness.industryCompounded preparationsTopical medicationClinical PracticeCross-Sectional StudiesFamily medicineDermatologic AgentsbusinessDermatologistsJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct